CEL-SCI Gets Independent Recommendation to Continue PH III Head and Neck Cancer Trial

CEL-SCI Corporation (NYSE American: CVM) announced on 8/15/18 that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data.